Yazan Batineh, Qutaiba Ahmed Al Khames Aga, Kawthar Faris Nassir, Tharwat I Sulaiman, Ali Abbas Al-Gharawi, Jawad I Rasheed, Zaid Al Madfai, Mutaz A. Sheikh Salem, Luma Ahmed Al Khames Aga, Manhal Yasseen Rijab Agha, Eamon Abdullah
email@example.com , firstname.lastname@example.org
Yazan Batineh1, Qutaiba Ahmed Al Khames Aga1*, Kawthar Faris Nassir2, Tharwat I Sulaiman2, Ali Abbas Al-Gharawi2, Jawad I Rasheed2, Zaid Al Madfai3, Mutaz A. Sheikh Salem1, Luma Ahmed Al Khames Aga4, Manhal Yasseen Rijab Agha5, Eamon Abdullah6
1Department of Clinical Sciences, Faculty of Pharmacy, Philadelphia University, Amman, Jordan.
2Bagdad Teaching Hospital, Medical City Baghdad, Iraq.
3College of Medicine, Baghdad University, Baghdad, Iraq.
4COVID-19 Testing Specialist Atechy Group Cardiff, Wales, UK.
5University Hospital of Wales, Department of Orthopedic Cardiff, UK.
6St. George’s University, Grenada, West Indies.
Volume - 15,
Issue - 11,
Year - 2022
Statins, which are widely used to treat hypercholesterolemia, have anti-inflammatory and antioxidant effects, upregulate angiotensin-converting enzyme 2 (ACE2) receptors, which happen to be SARS-CoV-2’s gateway into cells. This study aims to analyse the effects of Fenofibrate in comparison to Statins and a control group in patients with COVID-19. This is a retrospective open blind observational study of cohort of 300 patients experienced COVID-19 (symptoms’ severity varied between patients). The participants were divided into three cohorts; a control group received standard COVID-19 treatment (n=100); a second group (n=100) of patients who were on Statins, in addition they received the standard treatment; and a third cohort for patients who were already taking Fenofibrate (TRICOR®) as a medication to treat hyperlipidemia (n=100). Most symptoms (including cough, exertional dyspnoea, SOB, sore throat, sneezing, headache, tiredness, agitation, diarrhoea, joint pain, insomnia, myalgia, and fatigue) were less prevalent for patients who administered antihyperlipidemic drugs compared to the control group. Patients who were already taking Cholesterol-lowering medication presented with symptoms varied between mild to severe. Patients on Statins or Fenofibrate also showed less tachycardia and tachypnoea compared to those who were not on antihyperlipidemic drugs, and also the need for oxygen and ICU admission were less frequent. The length of stay in hospital was shorter in patients who were already on Statins or Fenofibrate. Both Statins and Fenofibrate have improved the outcome and the severity of symptoms for patients with Covid 19 infection.
Cite this article:
Yazan Batineh, Qutaiba Ahmed Al Khames Aga, Kawthar Faris Nassir, Tharwat I Sulaiman, Ali Abbas Al-Gharawi, Jawad I Rasheed, Zaid Al Madfai, Mutaz A. Sheikh Salem, Luma Ahmed Al Khames Aga, Manhal Yasseen Rijab Agha, Eamon Abdullah. Fenofibrate and Statins in Patients with COVID-19. Research Journal of Pharmacy and Technology. 2022; 15(11):5132-8. doi: 10.52711/0974-360X.2022.00863
Yazan Batineh, Qutaiba Ahmed Al Khames Aga, Kawthar Faris Nassir, Tharwat I Sulaiman, Ali Abbas Al-Gharawi, Jawad I Rasheed, Zaid Al Madfai, Mutaz A. Sheikh Salem, Luma Ahmed Al Khames Aga, Manhal Yasseen Rijab Agha, Eamon Abdullah. Fenofibrate and Statins in Patients with COVID-19. Research Journal of Pharmacy and Technology. 2022; 15(11):5132-8. doi: 10.52711/0974-360X.2022.00863 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-11-48
1. Rani D, Bajaj H, Singh R. SARS-COV-2 (COVID-19) and role of real time Reverse Transcription Polymerase Chain Reaction (RT-PCR) in its diagnosis. Research Journal of Pharmacy and Technology. 2021;14(6):3437-40.
2. Sree Lekshmi. R. S, P. Shanmugasundaram. Neuroprotective Properties of Statins. Research J. Pharm. and Tech 2018; 11(8): 3581-3584.
3. Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID-19. International Journal of Infectious Diseases. 2020;96:615-7.
4. Bifulco M, Gazzerro P. Statin therapy in COVID-19 infection: much more than a single pathway. European Heart Journal-Cardiovascular Pharmacotherapy. 2020.
5. Varga Z. Endotheliitis bei COVID-19. Der Pathologe. 2020;41(2):99-102.
6. Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, Meyer RF, et al. Real-time reverse transcription–polymerase chain reaction assay for SARS-associated coronavirus. Emerging infectious diseases. 2004;10(2):311.
7. Ansori ANM, Kharisma VD, Fadholly A, Tacharina MR, Antonius Y, Parikesit AA. Severe acute respiratory syndrome coronavirus-2 emergence and its treatment with alternative medicines: A review. Research Journal of Pharmacy and Technology. 2021;14(10):5551-7.
8. Shanmugasundaram P. Neuroprotective Properties of Statins. Research Journal of Pharmacy and Technology. 2018;11(8):3581-4.
9. Alaraj M. Pharmacological repurposed agents for COVID-19. Research Journal of Pharmacy and Technology. 2022;15(1):441-6.
10. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in lipid research. 2009;48(1):1-26.
11. Gupta S, Jain R, Kapur S. Statins: A Review of Wonder Drug from Fungus. Research Journal of Pharmacy and Technology. 2014;7(10):1201.
12. Kow CS, Hasan SS. Meta-analysis of effect of statins in patients with COVID-19. American Journal of Cardiology. 2020;134:153-5.
13. Butt, J. H., Gerds, T. A., Schou, M., Kragholm, K., Phelps, M., Havers-Borgersen, E., ... & Fosbøl, E. L. (2020). Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. BMJ open, 10(12), e044421. dx.doi.org/10.1136/bmjopen-2020-044421.
14. Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgraduate medicine. 2020;132(8):749-55.
15. Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. The American journal of cardiology. 2020;136:149-55.
16. Radenkovic D, Chawla S, Pirro M, Sahebkar A, Banach M. Cholesterol in relation to COVID-19: should we care about it? Journal of clinical medicine. 2020;9(6):1909.
17. Saber S, Khodir AE, Maghmomeh AO, Nouh NA, El-Baz AM. COVID-19 Pandemic: current Challenges and future Perspectives. Research Journal of Pharmacy and Technology. 2022;15(1):329-37.
18. Ahmad S, Shoaib A, Ali S, Alam S, Alam N, Ali M, et al. Epidemiology, risk, myths, pharmacotherapeutic management and socio economic burden due to novel COVID-19: a recent update. Research Journal of Pharmacy and Technology. 2020;13(9):4435-42.
19. Dawood AA, Altobje MA, Alnori HA-M. Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins. Research Journal of Pharmacy and Technology. 2021;14(9):4760-6.
20. Ehrlich A, Uhl S, Ioannidis K, Hofree M. BR tenOever, Y. Nahmias, The SARS-CoV-2 Transcriptional Metabolic Signature in Lung Epithelium, SSRN Electron J. 2020;10. http://dx.doi.org/10.2139/ssrn.3650499.
21. Bajwa EK, Malhotra CK, Thompson BT, Christiani DC, Gong MN. Statin therapy as prevention against development of acute respiratory distress syndrome: an observational study. Critical care medicine. 2012;40(5):1470. doi: 10.1097/CCM.0b013e3182416d7a.
22. Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. The American journal of cardiology. 2020;136:149-55. doi.org/10.1016/j.amjcard.2020.09.012.
23. Peymani P, Dehesh T, Aligolighasemabadi F, Sadeghdoust M, Kotfis K, Ahmadi M, et al. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients. Translational medicine communications. 2021;6(1):1-14. doi.org/10.1186/s41231-021-00082-5.
24. Zhang X-J, Qin J-J, Cheng X, Shen L, Zhao Y-C, Yuan Y, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell metabolism. 2020;32(2):176-87. e4. doi.org/10.1016/j.cmet.2020.06.015.